Current Treatment Options in Oncology

, Volume 14, Issue 2, pp 198–211

Current and Emerging Therapies in Mantle Cell Lymphoma

Lymphoma (LI Gordon, Section Editor)

DOI: 10.1007/s11864-013-0230-z

Cite this article as:
Brett, L.K. & Williams, M.E. Curr. Treat. Options in Oncol. (2013) 14: 198. doi:10.1007/s11864-013-0230-z

Opinion statement

Mantle Cell Lymphoma, characterized by the t(11;14)(q13; q32) chromosomal translocation and cyclin D1 expression, remains one of the most challenging lymphoma subtypes to treat. Therapy can be divided into treatment modalities for younger, stem cell transplant (SCT)-eligible patients vs older, SCT-ineligible patients. For clinically fit patients younger than 60–65 years of age we recommend cytarabine-containing induction and conditioning regimens such as Rituximab (R)-CHOP alternating with R-DHAP followed by autologous SCT consolidation. Elderly patients benefit from R-bendamustine or R-CHOP with maintenance rituximab following induction therapy, especially after R-CHOP. While standard chemoimmunotherapy provides high overall response rates, the responses are not durable and sequential therapies are thus necessary. MCL is proving to be sensitive to novel therapies that may in the near future become useful adjuncts to standard regimens. For example, bortezomib, lenalidomide, and temsirolimus each have single-agent efficacy in relapsed and refractory disease. Several targeted agents are emerging that likewise may transform management of MCL. The B-cell receptor pathway appears to be critical in the pathogenesis of MCL, and novel agents such as ibrutinib and idelalisib that target this signaling pathway are highly active in relapsed and refractory MCL. Similarly, cell cycle inhibitors targeting cyclin dependent kinases as well as HDAC inhibitors have shown promise in early studies.


Mantle cell lymphomaB-cell receptorCyclin D1IbrutinibLenalidomidemTOR inhibitorBortezomib Bendamustine

Supplementary material

11864_2013_230_MOESM1_ESM.docx (19 kb)
Supplemental Table 1Conventional therapy * = sentinel articles (DOCX 18 kb)

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Hematology/Oncology DivisionUniversity of Virginia Health SystemCharlottesvilleUSA